CONTACT: TOM MOORE
8788 John Pappajohn Pavilion
Iowa City IA 52242
Release: Aug. 7, 2000
Enrollment continues in landmark breast cancer study at UI, other sites
IOWA CITY, Iowa -- The first year of the multi-center Study of Tamoxifen
and Raloxifene (STAR) saw 6,139 postmenopausal women at increased risk of
breast cancer enroll in this landmark prevention study. More than 47,000 women
went through an individualized, no-obligation risk assessment to determine
their risk of breast cancer and weigh the pros and cons of joining the trial.
Enrollment began July 1, 1999. Researchers plan to eventually enroll 22,000
women in STAR.
Many of these 47,114 women did not have an increased risk of breast cancer
that would make them eligible for the trial. More than 29,300 women were eligible
for the trial based on breast cancer risk alone, but had to make the choice
to participate based upon their overall health and personal reasons.
"As of June 30, 2000, more than 136 women from Iowa are already participating
in STAR, including 82 women at University of Iowa Hospitals and Clinics,"
said Peter Jochimsen, M.D., a UI professor of surgery, surgical oncologist
and principal investigator on STAR. "This trial has a five-year recruitment
plan, but we hope to reach our goal within the next two or three years. We
are encouraging all eligible women who live in Iowa to participate."
STAR is designed to determine whether the osteoporosis prevention and treatment
medication raloxifene is as effective as tamoxifen in reducing breast cancer
risk. In 1998, tamoxifen was shown to reduce the chance of developing breast
cancer by about half in the Breast Cancer Prevention Trial (BCPT), a study
of more than 13,000 premenopausal and postmenopausal women at increased risk
of breast cancer. The U.S. Food and Drug Administration (FDA) approved tamoxifen
to reduce the incidence of breast cancer in October of 1998. Raloxifene was
shown to reduce the incidence of breast cancer in a large osteoporosis trial,
the MORE study.
More than 500 centers across the United States, Puerto Rico and Canada are
enrolling participants in STAR. STAR is a study of the National Surgical Adjuvant
Breast and Bowel Project (NSABP) and is supported by the U.S. National Cancer
NSABP Chairman Norman Wolmark, M.D., said, "We are pleased that so
many women have joined this trial to help us answer this important medical
question. We encourage women to go through the risk assessment process to
learn more about their breast cancer risk and about STAR.
In the end, each woman who joins does so for her own reasons, but every single
woman plays a vital role."
Women who participate in STAR must be postmenopausal, at least age 35 and
have an increased risk of breast cancer as determined by their age, family
history of breast cancer, personal medical history, age at first menstrual
period and age of first live birth. They also will go though a process known
as informed consent, during which they will learn about the potential benefits
and risks of tamoxifen and raloxifene before deciding whether to participate
Postmenopausal women in Iowa who are interested in participating in STAR
can contact UI Health Care at (319) 356-2778 or toll free at (800) 237-1225.
University of Iowa Health Care describes the partnership between the
UI College of Medicine and the UI Hospitals and Clinics and the patient care,
medical education and research programs and services they provide.